SCHEMBL2940366

SCHEMBL2940366

O=C1COCCN1c1cccc(F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K1 Q92918 5/20 0.50
PIK3CD O00329 4/20 0.48
NTRK1 P04629 1/20 0.47
PIK3CA P42336 2/20 0.46
PIK3CG P48736 2/20 0.46
DRD2 P14416 1/20 0.46
DRD3 P35462 1/20 0.46
PIK3CB P42338 1/20 0.46
FADS1 O60427 1/20 0.45
ALDH1A1 P00352 1/20 0.44
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
FAAH O00519 1/20 0.44
MGLL Q99685 1/20 0.44
HTR2C P28335 1/20 0.43
HTR2B P41595 1/20 0.43
F10 P00742 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20124865 0.83 PIK3CD (0.49) MAP4K1PIK3CDPIK3CAPIK3CGPIK3CB
SCHEMBL29740650 0.83 PIK3CD (0.49) MAP4K1PIK3CDPIK3CAPIK3CGPIK3CB
SCHEMBL20502398 0.81 ALDH1A1 (0.48) MAP4K1PIK3CDPIK3CAPIK3CGPIK3CB
SCHEMBL1438679 0.81 PIK3CD (0.46) MAP4K1PIK3CDPIK3CAPIK3CGDRD2
SCHEMBL13097259 0.81 F10 (0.49) MAP4K1PIK3CDPIK3CAPIK3CGPIK3CB
SCHEMBL10272402 0.81 ALDH1A1 (0.52) MAP4K1PIK3CDPIK3CAPIK3CGDRD2
SCHEMBL5740890 0.81 PIK3CD (0.51) MAP4K1PIK3CDPIK3CAPIK3CGDRD2
SCHEMBL18630668 0.80 F10 (0.54) F10PTGS2
SCHEMBL198132 0.80 PTGS2 (0.57) F10MEN1KMT2APTGS2
SCHEMBL793560 0.79 PIK3CD (0.47) MAP4K1PIK3CDPIK3CAPIK3CGPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10266532-B2 Tricyclic modulators of TNF signaling ABBVIE INC. (US) 2019-04-23 US disclosed
US-20180179198-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2018-06-28 US disclosed
EP-3288939-A1 TRICYCLIC MODULATORS OF TNF SIGNALING AbbVie Inc. (US) 2018-03-07 EP disclosed
US-9856253-B2 Tricyclic modulators of TNF signaling ABBVIE, INC. (US) 2018-01-02 US disclosed
WO-2016168641-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. (US) 2016-10-20 WO disclosed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 US disclosed
US-20100210864-A1 PROCESS FOR THE PREPARATION OF N-ARYLMORPHOLINONES DORSCH DIETER 2010-08-19 US disclosed
US-20100210864-A1 PROCESS FOR THE PREPARATION OF N-ARYLMORPHOLINONES DORSCH DIETER 2010-08-19 US disclosed
US-20100210864-A1 PROCESS FOR THE PREPARATION OF N-ARYLMORPHOLINONES DORSCH DIETER 2010-08-19 US disclosed
US-7687624-B2 Process for the production of N-arylmorpholinones MERCK PATENT GMBH (DE) 2010-03-30 US disclosed
US-7687624-B2 Process for the production of N-arylmorpholinones MERCK PATENT GMBH (DE) 2010-03-30 US disclosed
US-7687624-B2 Process for the production of N-arylmorpholinones MERCK PATENT GMBH (DE) 2010-03-30 US disclosed
CN-100537549-C Process for preparing N-aryl morpholinones MERCK PATENT GMBH (DE) 2009-09-09 CN disclosed
EP-1654240-B1 METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES MERCK PATENT GMBH (DE) 2006-11-02 EP disclosed
US-20060217550-A1 One pot process; cyclization; 4-(4-nitrophenyl)-3-oxomorpholine; Factor Xa inhibitors; , myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens MERCK PATENT GMBH (DE) 2006-09-28 US disclosed
CN-1832933-A Method for production of n-aryl morpholinones MERCK PATENT GMBH (DE) 2006-09-13 CN disclosed
EP-1654240-A1 METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES MERCK PATENT GmbH (DE) 2006-05-10 EP disclosed
WO-2005016899-A1 METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES MERCK PATENT GMBH (DE) 2005-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING TNF, TNFRSF1A, CD40 MAP4K1 276/4885PIK3CD 433/4885NTRK1 772/4885
US-20100210864-A1 PROCESS FOR THE PREPARATION OF N-ARYLMORPHOLINONES CYP1A1, CYP1B1, OPRM1 MAP4K1 884/4885PIK3CD 4679/4885NTRK1 923/4885
US-10266532-B2 Tricyclic modulators of TNF signaling TNF, TNFRSF1A, CD40 MAP4K1 276/4885PIK3CD 433/4885NTRK1 772/4885
US-20060217550-A1 One pot process; cyclization; 4-(4-nitrophenyl)-3-oxomorpholine; Factor Xa inhibitors; , myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens PLAT, PCSK9, SERPINE1 MAP4K1 2866/4885PIK3CD 4260/4885NTRK1 2088/4885
US-20180179198-A1 TRICYCLIC MODULATORS OF TNF SIGNALING TNF, TNFRSF1A, CD40 MAP4K1 276/4885PIK3CD 433/4885NTRK1 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.